Rights issue enables market expansion
September 18, 2018
The Board of Directors and the CEO of Phase Holographic Imaging PHI AB (publ), corporate identity number 556542-7811, hereby submit Interim Report 1 for the fiscal year 2018/19.
Read More
Kallelse till årsstämma i Phase Holographic Imaging PHI (publ)
August 28, 2018
Aktieägarna i Phase Holographic Imaging PHI AB (publ), 556542-7811, kallas härmed till årsstämma onsdagen den 26 september 2018 kl. 17.00 i bolagets lokaler, Scheelevägen 22 i Lund.
New CEO commentary: “Understanding Skin Cancer”
August 13, 2018
PHI’s CEO and founder Peter Egelberg comments the latest research results by the scientists at the PHI/UCSF Holographic Imaging Cytometry Center of Excellence.
Scientists at UCSF-PHI Center of Excellence map the genetic progression of invasive skin cancer
July 12, 2018
Utilizing precision genetic engineering and PHI’s HoloMonitor technology, scientists at University of California, San Francisco, have for the first time been able to monitor and map how mutations break down the genetic protection against skin cancer.
PHI´s new software available for customer delivery
July 9, 2018
In this first version of App Suite three common analyzes are included: cell proliferation, cell motility, and cell quality control. App Suite will be rapidly expanded with additional applications. HoloMonitor® App Suite 2.0 is scheduled to be released to customers in Q4 2018.
Kommuniké från extra bolagsstämma i Phase Holographic Imaging PHI AB (publ)
June 19, 2018
Igår, den 18 juni 2018, hölls extra bolagsstämma i Phase Holographic Imaging PHI AB (publ). Stämman röstande enhälligt för föreslagna beslut gällande nyemission.
PHI and BioSpherix sign co-marketing agreement
June 18, 2018
Phase Holographic Imaging (PHI) and BioSpherix recently signed a collaboration agreement aiming to co-market the companies’ complementary product lines. BioSpherix, NY USA, manufactures and markets advanced cell incubators.
Biostock interview with CEO Peter Egelberg
June 11, 2018
Interview with CEO Peter Egelberg (Swedish) on biostock.se where he talks about PHI’s progress, where PHI is right now and where PHI wants to be in the near future. “Our goal is to be top of mind when researchers and scientists worldwide are looking for a new cell analytic tool”. You find the interview here.
New CEO commentary — “Redefining aging with HoloMonitor”
June 4, 2018
In the CEO commentary “Redefining aging with HoloMonitor” Peter Egelberg comments on the promising research results that were recently reported by Australian television.
PHI at the Nordic Microscopy Society meeting, June 25-28
May 25, 2018
The Nordic Microscopy Society meeting in Lyngby Denmark offers several opportunities to meet with us and to hear about the latest HoloMonitor news.
